Physician profile
Michael E Gold
NPI 1750306155
$15,029.71
in general payments reported to CMS, 2019-2025
55 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,595 · 2020: $2,545 · 2021: $3,092 · 2022: $2,765 · 2023: $2,161 · 2024: $1,632 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,031.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,822.59 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $835.46 | 2019-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $813.92 | 2021-2025 | |
| Amgen INC. | $802.31 | 2019-2021 | |
| Lundbeck LLC | $710.86 | 2021-2025 | Vyepti |
| Emd Serono, INC. | $652.59 | 2020-2025 | Mavenclad |
| Biogen, INC. | $618.87 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Amneal Pharmaceuticals LLC | $586.92 | 2019-2025 | Rytary, Crexont |
| Lilly USA, LLC | $542.26 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Janssen Pharmaceuticals, INC | $535.26 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $511.35 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ucb, INC. | $464.00 | 2019-2024 | Briviact, Nayzilam |
| Allergan, INC. | $456.00 | 2020-2022 | |
| Upsher-Smith Laboratories LLC | $433.20 | 2020-2022 | |
| Pfizer INC. | $345.98 | 2021-2025 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.